Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/31/24
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent SalesZacks Investment Research • 10/31/24
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 10/28/24
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAIGlobeNewsWire • 10/24/24
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAIGlobeNewsWire • 10/24/24
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular EdemaGlobeNewsWire • 10/18/24
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/10/24